A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Patients With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
This study tests a new hormone-blocking drug called giredestrant combined with everolimus to see if it works better than standard hormone therapy plus everolimus. Researchers want to help patients whose estrogen receptor-positive, HER2-negative breast cancer has continued to grow after previous treatments.
You may be able to join if you have advanced or spreading breast cancer that is estrogen receptor-positive and HER2-negative. Participants must have previously been treated with hormone therapy and CDK4/6 inhibitor drugs, and be willing to provide a blood sample for genetic testing.
Participants will be randomly assigned to receive either the experimental drug giredestrant combined with everolimus or standard hormone therapy combined with everolimus. Your health and the response of your cancer will be closely monitored by the study team throughout the process.
The study has locations in several U.S. states including Alaska, Arizona, and Arkansas. This study is currently active, but it is not looking for new participants right now.
- 1Testing a new combination of giredestrant and everolimus
- 2For adults with advanced estrogen-positive, HER2-negative breast cancer
- 3Compares the study treatment against standard hormone therapy options
Related video
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.